Tetra Radar · FDA Approvals · Decision date
relacorilant: FDA decision date
Corcept Therapeutics Incorporated (CORT) · 17 December 2026
Relacorilant for patients with Cushing’s syndrome – Resubmitted New Drug Application Prescription Drug User Fee Act (PDUFA) date of December 17, 2026.
Source: 8-K of 3 November 2026
The decision is pending.
Corcept Therapeutics Incorporated on Tetra Radar
A PDUFA date is the date by which the FDA has said it will decide on an application. Dates can move, and a decision is not an approval. Tetra Radar observes public information for research purposes. It does not provide investment advice.